The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July. Here's why.

| More on:
A medical researcher works on a bichip, indicating share price movement in ASX tech companies

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in ASX healthcare company Polynovo Limited (ASX: PNV) almost doubled in price last year. And, despite a shaky start to 2021, at their current price of $2.62 they are still up over 100% versus their March 2020 low of $1.275.

For investors willing to weather the volatility in the share price, Polynovo has delivered some significant gains – it wasn't all that long ago that the company's shares were trading consistently below $1, and in December they touched a record high of $4.08.

But there is another under-the-radar junior biotech company currently trading on the ASX that operates in the same sector as Polynovo.

New Zealand-based healthcare company Aroa Biosurgery Limited (ASX: ARX) listed on the ASX in July last year after raising $45 million at $0.75 a share. The Aroa share price has already surged 63% higher than its IPO price to $1.22 as at the time of writing, meaning the company now has a market cap of a touch under $367 million.

What does Aroa do?

Like Polynovo, Aroa specialises in the development of biodegradable medical devices that aid in skin tissue repair. Aroa's flagship product is called Endoform and is originally derived from a sheep's forestomach. When applied to complex wounds and severe skin injuries, Endoform aids in tissue repair and regeneration, encouraging new skin growth.

Aroa claims its product has delivered superior results versus current market leaders across a range of qualitative factors in preclinical studies. It also claims its product is 20% to 60% less expensive than those of its competitors.

Recent news out of the company

In its most recent market update, covering the December quarter, Aroa reported quarterly cash receipts of NZ$5.9 million, an uplift of 44% over the September quarter, reflecting an improvement in market conditions. Despite the challenges posed by COVID-19, the company – which reports its financial results based on the New Zealand financial year ending 31 March – believes it is still on track to deliver revenue growth for the second half of FY21 versus second half FY20.

It also announced that Endoform, as well as another of its regenerative tissue solutions, Myriad, had received regulatory approval in India. Aroa estimates that the advanced wound care market in India was valued at between US$225 million and US$485 million in 2020.


With only the March quarter left in FY21 for Aroa, it believes it is on track to deliver revenue of NZ$21 million for the year on a constant currency basis. This would be slightly below its FY20 revenue of NZ$22 million.

However, the company is expanding. Now that it has secured regulatory approvals to distribute its products in India, it is appointing a distribution team and plans to begin rolling out its products in the second half of this calendar year.

For its part, Aroa is feeling bullish about its future prospects. The company is in the process of expanding its manufacturing facility in order to meet the expected rise in demand for its products over the next 3 years. And, in an announcement released to the market earlier this week, the company stated that it planned to expand its direct sales team in the US, in a move "expected to positively impact medium-term sales".

Rhys Brock has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 300 healthcare stock is surging 13% on FDA news

Here's what's getting investors excited today.

Read more »

an angry man in a suit stands with his hands outstretched in a questioning gesture of annoyance and displeasure while an airport check in attendant is on the telephone in the background.
Earnings Results

This ASX 200 healthcare stock is sinking 6% despite explosive first-half earnings growth

Sometimes the market just expects too much from companies.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

2 ASX healthcare shares with 'compelling' valuations to buy

The QVE team reckons this pair of small caps can be bought for cheap right now, but could rocket very…

Read more »